by enhancing quality and
yield of lentiviral vectors
by enhancing quality and
yield of lentiviral vectors
Emerging advanced therapies such as CAR-T and gene therapies have the potential to cure previously intractable conditions with a single infusion. Unfortunately, these incredible treatments remain out of the reach of many due to the very high cost of treatment. High price tags are driven by the very high production costs associated with producing components such as lentivirus. This is because the manufacturing yield and quality for lentivirus are low when compared to the quantity required for the therapy.
Lentitek has developed a unique manufacturing technology that can significantly improve the production quality of the lentivirus vector used in advanced therapies. This improvement in manufacturing quality can lead to higher manufacturing yields and improved product potency. We can also bring you additional benefits in payloads which are normally difficult to handle. Discover how we can offer these benefits on the link below
Using a novel promoter, our proprietary method for producing lentivirus can increase the quality and yield of your vector by significantly reducing vector genome splicing and payload breakthrough expression
The Lentitek approach is easy to integrate into your current production method and does not require any changes to be made to the vector genomic sequence
Our technology can be applied to both transient transfection as well as integrated into a stable cell line production to suit a wide range of production scenarios
Floor 3, 1-4 Atholl Crescent, Edinburgh, EH3 8HA, United Kingdom
Copyright © 2024 Lentitek Ltd - All Rights Reserved.